Targeted Oncology3d
Mitigating Toxicities With Oral SERDs and Other Breast Cancer Therapies
Seth Wander, MD, PhD, discusses the tolerability of selective estrogen receptor degraders and next-generation anti-estrogen ...
Clinical Pain Advisor4d
Reduced Lifetime Estrogen Exposure Linked to Risk for ACPA-Negative IA
Postmenopausal women with CSA were associated with an increased risk of developing ACPA-negative IA and progressing to RA.
Center for Biosimilars11d
FDA Approves Another Pair of Denosumab Biosimilars, Conexxence and Bomyntra
The FDA approved another set of denosumab biosimilars, Conexxence/Bomyntra (denosumab-bnht), expanding treatment options for ...
Medscape13d
Acute Arthritis in Traveller Reveals Rare Viral Infection
This case emphasises the need for early recognition and proper diagnosis of CHIKV infection in patients with acute joint pain ...
Mena FN13d
Theratechnologies Receives FDA Approval For EGRIFTA WR™ (Tesamorelin F8) To Treat Excess Visceral Abdominal Fat In Adults With HIV And Lipodystrophy
MONTREAL, March 25, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the“Company”) (TSX: TH) (NASDAQ: THTX), a commercial-stage biopharmaceutical company, today announced that ...
Medscape25d
Four Clinical Variables Help to Predict Rheumatoid Arthritis Development in At-Risk Individuals With Joint Pain
In individuals with seropositive arthralgia, the risk of developing rheumatoid arthritis (RA) rose in the presence of high titers of anti–citrullinated peptide antibodies (ACPAs) and ...
MedPage Today28d
First Omalizumab Biosimilar Approved
The most common adverse reactions varied by indication and age. For asthma in patients ≥12 years, arthralgia, general pain, leg pain, fatigue, dizziness, fracture, arm pain, pruritus ...